Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

23. Dezember 2024 11:37 ET | Quelle: Research and Markets

Glioblastoma Multiforme Treatment (GBM) Market Research Report 2024-2030: Focus on Radiation Therapy, Surgery, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy, Immunotherapy

Dublin, Dec. 23, 2024 (GLOBE NEWSWIRE) -- The "Glioblastoma Multiforme Treatment (GBM) - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global...
24. Dezember 2021 07:13 ET | Quelle: Research and Markets

Global Glioblastoma Multiforme (GBM) Industry Landscape, 2030 - Featuring Genentech, Merck, VBL Therapeutics, Diffusion Pharma, Bayer, and More

Dublin, Dec. 24, 2021 (GLOBE NEWSWIRE) -- The "Glioblastoma Multiforme (GBM) - Market Insight, Epidemiology and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering. ...
01. Dezember 2021 05:13 ET | Quelle: Research and Markets

Global Glioblastoma Multiforme Treatment Markets Analysis & Forecasts, 2017-2020 & 2021-2028

Dublin, Dec. 01, 2021 (GLOBE NEWSWIRE) -- The "Glioblastoma Multiforme Treatment Market Size, Share & Trends Analysis Report By Treatment (Radiation Therapy, Immunotherapy), By Drug Class, By...
22. November 2021 09:25 ET | Quelle: Lixte Biotechnology Holdings, Inc.

LIXTE BIOTECHNOLOGY HOLDINGS, INC. ANNOUNCES THAT ENROLLMENT HAS RESUMED IN NATIONAL CANCER INSTITUTE’S TRIAL TO DETERMINE ABILITY OF LIXTE COMPOUND LB-100 TO ENTER RECURRENT, MALIGNANT BRAIN TUMORS

PASADENA, CA, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT) announced that the National Cancer Institute (NCI) has resumed enrolling patients into their...